Australian life science company, QBiotics will present recent positive efficacy data from its completed phase I trial of its lead cancer drug, tigilanol tiglate, at Biotech Showcase.
Tigilanol tiglate is a novel small molecule diterpene ester in development as a local treatment for a range of solid tumors, initially focussed on Head and Neck Squamous Cell Carcinoma (HNSCC).
In 2018, there were 18.1 million newly diagnosed cases of cancer globally, with solid tumors accounting for 90% of all cancers. Meanwhile, HNSCC is the 7th most common cancer globally, with around 1.38 million new cases reported in 2018.
At Biotech Showcase, QBiotics CEO Dr. Victoria Gordon will speak about the positive data from the company’s completed phase I study of tigilanol tiglate in solid tumors.
The data showed that tigilanol tiglate was generally well tolerated and doses escalated from 0.06 to 3.60 mg/m2, without reaching a maximum tolerated dose.
Patients had a range of tumor types including squamous cell carcinoma, basal cell carcinoma, melanoma, breast adenocarcinoma, atypical fibroxanthoma, atypical myxoid fibrosarcoma, metastatic colorectal adenocarcinoma, adenoid cystic carcinoma and angiosarcoma. Clinical activity was observed in all nine tumour types, even at the lowest doses, with four patients attaining a Complete Response (total tumor destruction).
"Given the sound safety profile, and positive antitumor responses observed, these results support further development of tigilanol tiglate as a potential treatment of solid tumors, and a very important advancement for our pharmaceutical," said QBiotics Group CEO and Managing Director, Dr Victoria Gordon.
Dr Gordon will also speak about the company’s phase I/II trial of tigilanol tiglate in patients with HNSCC, with the first patient successfully dosed in December. She will also talk about encouraging preclinical results from tigilanol tiglate combination with check point inhibitor drugs as well as QBiotics’ potential veterinary blockbuster treatment, STELFONTA®, which is being developed to treat mast cell tumors – the most common cancer in dogs.
Dr Gordon will present to on Tuesday 14th January at 2.00pm.
The company presentation will be available through the Biotech Showcase website. Following the meeting, the presentation will be available on the company website.
ABOUT QBIOTICS
QBiotics is a public unlisted Australian life sciences company which discovers, develops and commercialises novel anticancer and wound healing small molecules for human and veterinary markets. Its lead product, tigilanol tiglate, is an anticancer pharmaceutical targeting a range of solid tumors across multiple species. QBiotics' business model is to develop products that have application in both human and veterinary markets. Success in the veterinary programs validates QBiotics' technology and de-risks human development, while generating early, non-diluting revenues.
More information: https://qbiotics.com
ABOUT TIGILANOL TIGLATE
Tigilanol tiglate is a novel, small molecule undergoing development as an intratumoral injection treatment for solid tumors. Its effect on tumors is multimodal and involves direct local effects on the injected tumor as well as effects on distal, non-injected tumours. Complete destruction of the injected tumour is mediated via tumour vascular disruption as well as death of tumour cells by oncosis. Following tumor destruction, rapid wound healing of the site has been shown to ensue.
